Oncology

Your Article Summary

See Latest Articles

Clinical implications of hypoxia inducible factor in renal cell carcinoma
Urologic Oncology: Seminars and Original Investigations, 07/01/09

Smaldone MC et al. - In a review of the clinical implications of hypoxia inducible factor (HIF) in renal cell carcinoma (RCC), this report provides a directed review of recent discoveries defining the role of HIF in renal tumorigenesis and their relevance to clinical advances in targeted therapy for advanced RCC.

• Management of RCC has made considerable strides in the past decade, due in large part to identification of the von Hippel Lindau (VHL) tumor suppressor as a negative regulator of HIF-α protein expression.

• Stabilization of HIF-α appears to be critical for renal tumorigenesis, and is observed even in VHL-independent RCC.
• An understanding of the pathways that regulate expression and activation of the different HIF-α isoforms is key to delineating the mechanism of renal transformation and for development of novel therapeutics.
• A number of agents targeting HIF-α or its transcriptionally-regulated genes have shown promise in treatment of RCC.
• More effective treatment strategies are still needed.

Today in Renal/Urologic...keeping you current

Receive free subspecialty "5-minute updates" via email

Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09

Zinc and prostatic cancer
Current Opinion in Clinical Nutrition & Metabolic Care, 10/14/09

Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy
Annals of Oncology, 10/16/09

See All of Renal/Urologic